

"FDA-CTP AND CDISC DEVELOP TOBACCO DATA STANDARDS TO ACHIEVE EFFICIENCIES FOR ALL STAKEHOLDERS"

Presented by Chrissie Cai Data Quality Management Team Supervisor, DRSI, OS, CTP, FDA Presented by Christine Connolly Head of Standards Projects, CDISC

27 April 2023

Disclaimer: This is not a formal dissemination of information by FDA and does not represent Agency position or policy.

CENTER FOR TOBACCO PRODUCTS

THE TOBACCO CONTROL ACT BECAME LAW ON JUNE 22, 2009

FDA

- To regulate tobacco products and ensure that FDA had the authority to address issues of concern, especially tobacco dependence and the use of tobacco by young people Congress passed the Tobacco Control Act
- FDA's goal is to reduce the harm from all regulated tobacco products across the entire U.S. population:
 - Reducing the number of people who start using tobacco products
 - Encouraging more people to stop using these products
 - Reducing the adverse health impact for those who continue to use these products

THE TOBACCO CONTROL ACT'S AUTHORITIES

The Tobacco Control Act amended the Federal Food, Drug, and Cosmetic Act (FD&C) to provide FDA authority for:

- Premarket review of new and modified risk tobacco products
- Postmarket surveillance
- Product standards
- Testing and reporting of ingredients
- Reporting of harmful and potentially harmful constituents
- Adverse event reporting
- New warning labels
- Advertising and promotion restrictions
- User fees

FD

In general, FDA's tobacco regulatory authorities do not extend to:

- Setting tax rates for tobacco products
- Regulating therapeutic products, such as those marketed to treat tobacco dependence (regulated by other parts of FDA)
- Setting clean indoor air policies
- Regulating tobacco growing
- Requiring the reduction of nicotine yields to zero
- Providing cessation services
- Banning all cigarettes, smokeless tobacco products, little cigars, other cigars, pipe tobacco, or roll-your-own tobacco products
- Changing the minimum age of sale for tobacco products

ABOUT CTP



• Vision Statement

To make tobacco-related death and disease part of America's past, not America's future and, by doing so, ensure a healthier life for every family.

• Mission Statement

To protect Americans from tobacco-related death and disease by regulating the manufacture, distribution, and marketing of tobacco products and by educating the public, especially young people, about tobacco products and the dangers their use poses to themselves and others.

- Key Strategic Priorities
 - Product Standards
 - Comprehensive FDA Nicotine Regulatory Policy
 - Pre & Post-Market Controls; Regulations & Product Reviews
 - Compliance and Enforcement
 - Public Education



- CTP Data Standards Strategy 2021-2025
 - Purpose: Strategies for the development and dissemination of data standards to better support the programs of CTP through better, more meaningful data.
 - Areas that are included
 - Electronic Data Exchange Standards
 - Premarket and Postmarket Review
 - Quality
 - Policy
 - Planning and Governance

- Electronic Data Exchange Standards
 - <u>Technical Specification Document</u>
 - Electronic Submissions through CTP Portal or Electronic Submission Gateway (ESG)
 - Utilize the Appendix A example for Organization of Folders and Documents
 - Electronic submissions must be packaged using <u>eSubmitter</u>
 - Data files such as Excel (xls, xlsx) or sas transport files (xpt or xport) should not be converted to a PDF
 - Best Practices
 - Obtain an Industry Account Manager account for CTP Portal
 - Submit applications electronically utilizing eSubmitter and CTP Portal
 - Follow recommendations in the Technical Specification Document
 - Future State
 - Functionality and/or tools to assist submitters in organizing and packaging submissions
 - Validations built into tools to assist submitters in correcting issues prior to submission

Premarket and Postmarket Review

– <u>OMB Forms</u>

- Required forms for Premarket Tobacco Product Application and Substantial Equivalence Applications were released when the rules were published 10/4/2021 and the supporting OMB Forms were published in January 2022.
- Form 4057b: Product Application Grouping Spreadsheet is utilized to standardize product information contained within a submission until such time that a data standard is available.
- Similar forms are forthcoming for Substantial Equivalence and Exemption applications
- Best Practices
 - Always obtain the most recent form from FDA.gov. Do not re-use previously downloaded forms.
 - Submit 4057b with all PMTA applications
 - Complete the required fields defined by product category and sub-category
 - Do NOT change form fields, data drop downs or file format. Submit the file as an .xlsx
- Future State
 - Evaluating development of tools to assist submitters in populating form prior to submission



CTP DATA STANDARDS GRANT PROGRAM

- The Grant program has published for public participation under RFA-FD-22-002
- This is a Cooperative Agreement grant which is a support mechanism used when there will be substantial Federal scientific or programmatic involvement. Substantial involvement means that, after award, FDA scientific or program staff will assist, guide, coordinate, or participate in project activities
 - THE GRANTEE IS THE LEAD
- Outlines CTP Data Standards Program strategic goals
 - Support open, consensus-based, data standards development
 - Maintain and promote a well-defined data standards governance function,
 - Promote electronic submission of regulatory data using established standards
 - Optimize CTP's regulatory review process to fully leverage data conformed to standards

FDA

- Benefits to Industry
 - Reduces time for reviewers to locate and identify required documents
 - Validations can be built into the portal and/or packaging tools to assist Industry in submitting the necessary information required for a particular submission
 - Standardized structured data allows for validation criteria to be built into tools
 - Aligns CTP with FDA Data Standards Catalog in the use of data standards and supporting tools
 - Standardized data helps CTP to streamline the review process by organizing files and data and enabling search and automation capabilities
 - Controlled terminology ensures that the same words mean the same thing to both industry and FDA.
 - Improves collaboration and communication between FDA and Stakeholders
 - FDA leverages form data to obtain administrative information, help determine review types, and populate databases to enable the use of technology for review and analysis

TOBACCO IMPLEMENTATION GUIDE (TIG)

FDA

- Tobacco Implementation Guide (TIG):
 - Supports the CTP Data Standards Strategy 2021-2025 through provision of standards and terminologies to facilitate tobacco research, scientific review, harm reduction, and information exchange
 - Is a collaborative initiative with FDA-CTP, CDISC, and industry stakeholders
 - To develop non-proprietary, consensus-based, vendor-neutral, platform-independent submission data standards for tobacco product data
 - Will develop a set of standards, collectively referred to as **TIG v1.0**, to be freely available on the CDISC website with publication planned in 2023

TOBACCO IMPLEMENTATION GUIDE (TIG) V1.0

• A single, comprehensive implementation guide designed for use cases unique to tobacco studies



FD





- Address concepts for tobacco studies and translates them into CDISC standards; both:
 - Established CDISC standards
 - New CDISC standards to fill gaps identified by FDA-CTP and Industry SMEs
- Standards you will see as part of this project include:

Clinical Data Acquisition Standards Harmonization (CDASH) ≻Consistent data collection	Study Data (SDTM) ≻Organization		Analysis Dataset Model (ADaM) >Datasets and metadata to support clinical trial statistical analyses		
	Terminology inology for use across		n of adherence		

TIG TEAM AND TIMELINES





22-Mar	22-Apr	22-May	22-Jun	22-Jul	22-Aug	22-Sep	22-Oct	22-Nov	22-Dec	23-Jan	23-Feb	23-Mar	23-Apr	23-May	23-Jun	23-Jul	23-Aug	23-Sep	23-Oct	23-Nov
	Scoping																			
	Concept Modeling										Education & Communication									
		Standards Development											Interna	l Review	Public Review				Publication	Wrap-up
		QRS Development																		
		Data Science																		



CENTER FOR TOBACCO PRODUCTS

PROGRESS

- ✓ Scope and Requirements for TIG v1.0 are complete
- ✓ Key concepts are identified
- Standards development is complete via four workstreams
- Internal Review is in progress
- Data Science strategy/platforms are in progress
- Education & Communication started; training development in progress
- Conference presentations in 2022 and 2023 to raise awareness



Draft

FD)

- Introduction
- Standards for Tobacco Product Data
 - How To Determine Where Data Belong
 - How Standards Work Together
 - How to Use Controlled Terminology and Formats
 - About Questionnaires, Ratings, and Scales
 - Conformance to Standards
 - Guidance for Datasets
 - > Standards for Collection
 - > Standards for Tabulation
 - > Standards for Analysis
 - Standards for Data Exchange
- Examples
- > Appendices



The TIG v1.0 is CDISC's first *hybrid* implementation guide.

- Developed in partnership with the FDA-CTP, the TIG v1.0 is a stand-alone CDISC foundational standard that serves as a comprehensive resource for the collection, tabulation, analysis, and exchange of tobacco product data for submissions to FDA-CTP.
- The TIG v1.0 implements the following models:
 - CDASH Model v1.2
 - SDTM v2.1
 - ADaM v2.1
 - With references to standards and resources including Define-XML v2.1 and CDISC eCRF Portal

HYBRID IMPLEMENTATION GUIDE STRATEGY

Philosophy for development:

Adhere to Plain Writing: It's the Law! | FDA

Suggested in team kick-off.

- <u>https://www.plainlanguage.gov/guidelines/</u>, as much as possible
- Orient implementation guide to 1) Data, 2) Users, and 3) Standards in this order
- Ensure guidance is simplified, concise, and organized from highest level concepts to detailed concepts
- Adhere to scope of implementation of standards only (i.e., like an instruction manual)
- Limit content related to:
 - Historical or theoretical topics better covered in CDISC Knowledge Base articles, glossaries, and/or training
 - Regulatory requirements that are defined and managed by FDA-CTP
 - Guidance for using external standards, e.g., ISO 8601, best covered by the external organization

INNOVATION HIGHLIGHTS

 The TIG v1.0 focuses on implementation for use cases inherent to tobacco product data comprised of concepts identified by one or more stakeholders as important in the context of tobacco product research.

The following use cases are specifically addressed in the TIG:

- *Product Description*, which refers to concepts used to characterize tobacco products.
- *Nonclinical*, which refers to concepts used to identify potential risks and effects on biological processes for tobacco products via in vitro and in vivo nonclinical studies.
- Product Impact on Individual Health, which refers to concepts used to assess the impact of tobacco products on individuals.
- Product Impact on Population Health, which refers to concepts used to assess the impact of tobacco products on populations of individuals.

Draft



PRODUCT DESCRIPTION EXAMPLE

Tobacco Product Identifiers and Descriptors (TO)

Tobacco Products (TO) is a study reference dataset (see Tobacco Product Identifiers and Descriptors (TO)) that provides a mechanism for uniquely identifying a tobacco product. It is the origin of the sponsor-defined tobacco product identifier (SPTOBID). This identifier is additionally used in any dataset containing records that pertain to the product, at all stages of the product development lifecycle.

The example below illustrates TO concepts using a cigarette product for demonstration purposes. The Product Design Parameters and Conformance Testing section additionally demonstrates this dataset for an ENDS product and a portioned snus product.

✓ to.xpt

to.xpt

- **Rows 1-4:** Show the records for the product identifiers for the tobacco product identified in SPTOBID. These records are categorized as product identifiers by TOCAT = PRODUCT IDENTIFIERS.
- **Rows 5-10:** Show the records for the product descriptors for the tobacco product identified in SPTOBID. These records are categorized as product identifiers by TOCAT = PRODUCT DESCRIPTOR.

Row	STUDYID	DOMAIN	SPTOBID	TOSEQ	TOPARMCD	TOPARM	TOCAT	TOVAL	TOVALU
1	TOB07	TO	CIG01a	1	TBPRDCAT	Tobacco Product Category	PRODUCT IDENTIFIER	Cigarette	
2	TOB07	TO	CIG01a	2	TBPRSCAT	Tobacco Product Subcategory	PRODUCT IDENTIFIER	Filtered, Combusted	
3	TOB07	TO	CIG01a	3	MANUF	Manufacturer	PRODUCT IDENTIFIER	Joes Cigs USA	
4	TOB07	TO	CIG01a	4	TRADENAM	Trade Name	PRODUCT IDENTIFIER	Treetop Menthol King Size	
5	TOB07	TO	CIG01a	5	PACKTYP	Package Type	PRODUCT DESCRIPTOR	HARD PACK	
6	TOB07	TO	CIG01a	6	PRDQUAN	Product Quantity	PRODUCT DESCRIPTOR	20	CIGARETTE
7	TOB07	TO	CIG01a	7	LENGTH	Length	PRODUCT DESCRIPTOR	86.0	mm
8	TOB07	TO	CIG01a	8	CIRCUMF	Circumference	PRODUCT DESCRIPTOR	26.0	mm
9	TOB07	TO	CIG01a	9	VENTLTN	Ventilation	PRODUCT DESCRIPTOR	10.0	%
10	TOB07	TO	CIG01a	10	CHARFLAV	Characterizing Flavor	PRODUCT DESCRIPTOR	MENTHOL	



Draft

NONCLINICAL IN VITRO EXAMPLE



Bacterial Reverse Mutation Test (Ames) (GT)

Draft

Rows 1-7: Show values collected for the trial set, SetA.

Rows 8-16: Show values collected for the trial set, SetF. Revertent colonies were counted and each value is associated with a record to show a postfix of code of "V".

Rows 17-19: Show values collected for the trial set, SetG. Each record for this EUID shows the postfix code of "T". No revertent colonies were counted and there are no summary values collected.

Rows 20-25: Show values collected for the trial set, SetR.

Rows 6-7, 14-16, 23-25: Show summary values collected (e.g., MEAN, STANDARD DEVIATION, and/or FOLD INCREASE) that apply to the entire trial set, as indicated by the LVLDESC=TRIAL SET for these REFID values in the relref dataset.

gt.xpt.xpt

Row	STUDYID	ASSAYID	DOMAIN	GTSEQ	REFID	GTTESTCD	GTTEST	GTORRES	GTORRESU	GTCOLSRT	GTSTRESC	GTSTRESN	GTSTRESU	GTSTAT	GTREASND	GTMETHOD	GTDTC
1	8325064	Ames	GT	1	0_1	RPP	Revertant Numbers Per Plate	26	COLONIES		26	26	COLONIES			INSTRUMENT COUNTED	2015- 08-03
2	8325064	Ames	GT	2	0_2	RPP	Revertant Numbers Per Plate	35	COLONIES		35	35	COLONIES			INSTRUMENT COUNTED	2015- 08-03
3	8325064	Ames	GT	3	0_3	RPP	Revertant Numbers Per Plate	39	COLONIES		39	39	COLONIES			INSTRUMENT COUNTED	2015- 08-03
4	8325064	Ames	GT	4	0_4	RPP	Revertant Numbers Per Plate	35	COLONIES		35	35	COLONIES			INSTRUMENT COUNTED	2015- 08-03
5	8325064	Ames	GT	5	0_5	RPP	Revertant Numbers Per Plate	30	COLONIES		30	30	COLONIES			INSTRUMENT COUNTED	2015- 08-03
6	8325064	Ames	GT	6	А	RPP	Revertant Numbers Per Plate	33.0	COLONIES	MEAN	33.0	33.0	COLONIES				2015- 08-03
7	8325064	Ames	GT	7	А	RPP	Revertant Numbers Per Plate	5.0	COLONIES	STANDARD DEVIATION	5.0	5.0	COLONIES				2015- 08-03
8	8325064	Ames	GT	1	6_1	RPP	Revertant Numbers Per Plate	8	COLONIES		8	8	COLONIES			MANUALLY COUNTED	2015- 08-03
9	8325064	Ames	GT	2	6_1	сутотох	Cytotoxicity	Very thin background bacterial lawn			v						2015- 08-03
10	8325064	Ames	GT	3	6_2	RPP	Revertant Numbers Per Plate	10	COLONIES		10	10	COLONIES			MANUALLY COUNTED	2015- 08-03

19 27 April 2023 | FDA-CDISC Data Standards

CENTER FOR TOBACCO PRODUCTS

DATA SCIENCE INNOVATION

. ..

- CDISC Library
- End-to-end standards for tobacco studies
- Inclusion of informative content (e.g., domain assumptions and examples)
- Biomedical Concepts available
- ODM-XML representations of case report forms

FD

HOW YOU CAN BE INVOLVED

- We invite you to contribute to development of TIG standards.
 - Become a Tobacco Implementation Guide (TIG) volunteer
 - www.cdisc.org/volunteer
 - Click link to Become a Volunteer
 - Time commitment is generally a one-hour weekly meeting
 - It is never too late to volunteer.
 - Review draft standards as they are released
 - Please reach out with any questions or support you may need.
 - Christine Connolly, CDISC Head of Standards Projects: cconnolly@cdisc.org





THANK YOU



• We welcome your questions and feedback!